Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Completed Phase 1Phase 2 Interventional Results available

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

NCT01026493
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days, ABT-888 40 mg x 21 days, Temozolomide 150 mg x 5 days, ABT-888 40 mg x 5 days
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Zinc Intake on Essential Fatty Acid Metabolism

NCT03451214
View directory record Official record
Conditions
Inflammation, Oxidative Stress, Dyslipidemias
Interventions
Diet Zinc
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 22, 2026, 3:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Histologic Evaluation of Tissue Following Lutronic System Exposure

NCT04207047
View directory record Official record
Conditions
Abdominoplasty
Interventions
Genius, eC02, PicoPlus, LaseMD, LaseMD Flex
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting No phase listed Observational

Complex Adult Deformity Surgery (CADS)

NCT04194138
View directory record Official record
Conditions
Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
Interventions
Index or spine revision surgery for complex adult spinal deformity
Procedure
Lead sponsor
International Spine Study Group Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
17
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

NCT06294548
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Valemetostat, Atezolizumab, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

NCT00981799
View directory record Official record
Conditions
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Interventions
Nelarabine, Etoposide, Cyclophosphamide, Methotrexate, Filgrastim
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

NCT01442532
View directory record Official record
Conditions
Healthy Male Volunteer
Interventions
JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Results available

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

NCT00320749
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Docetaxel, Gemcitabine
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Evaluating Procedures for a Study of the AYA Survivors Coping and Emotional Needs Toolkit

NCT06420193
View directory record Official record
Conditions
Depression, Cancer, Adolescent, Young Adult, Adult
Interventions
AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
15 Years to 39 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 22, 2026, 3:36 PM EDT
Not listed Early Phase 1 Interventional

Spinal Fusions Steroid Study

NCT05287035
View directory record Official record
Conditions
Spinal Fusion
Interventions
Dexamethasone injection, Saline injection
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
10 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Phase 3 Interventional

Repurposing Low-Dose Clonidine for PTSD in Veterans

NCT04877093
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder, Sleep
Interventions
Clonidine Pill, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Our Voices Matter: Intervention for Depression in Youth

NCT07216326
View directory record Official record
Conditions
Depressive Symptoms, Allostatic Load, Metabolic Syndrome
Interventions
Racial Justice Activism Intervention ARM, Adulting 101- Control Arm
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
15 Years to 20 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vestibular Precision: Physiology & Pathophysiology

NCT04890132
View directory record Official record
Conditions
Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2, Vestibular Disorder
Interventions
VOR precision training
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Not applicable Interventional

Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting

NCT07410598
View directory record Official record
Conditions
Parkinson Disease, Deep Brain Stimulation
Interventions
Biphasic deep brain stimulation, Conventional deep brain stimulation, Theta burst deep brain stimulation, Multi frequency deep brain stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed No phase listed Observational

Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)

NCT04339998
View directory record Official record
Conditions
Coronavirus Infection, COVID, Covid-19, SARS-CoV-2
Interventions
Point-of-Care Ultrasonography (POCUS)
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Feasibility and Preliminary Efficacy of a Reverse Diet as a Novel Weight Loss Maintenance Strategy for Weight-Reduced Adults With Overweight/Obesity

NCT03560635
View directory record Official record
Conditions
Overweight and Obesity, Weight Loss Maintenance, Dietary Habits
Interventions
Weight Loss Maintenance (Control vs. Reverse Diet)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Not applicable Interventional

Empower@Home: Hybrid Effectiveness-Implementation Randomized Controlled Trial (RCT)

NCT06584422
View directory record Official record
Conditions
Depression
Interventions
Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression, Telephone friendly visits
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 3:36 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403 (Eptinezumab), Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

NCT05606237
View directory record Official record
Conditions
Myopia
Interventions
Low-level Red Light Therapy Device
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 13 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Acupuncture in Spinal Cord Injury Subjects

NCT03197675
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Acupuncture
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Social Media Obesity Treatment for College Students

NCT02342912
View directory record Official record
Conditions
Obesity
Interventions
Social Media Treatments
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 35 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 22, 2026, 3:36 PM EDT
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 22, 2026, 3:36 PM EDT